JP2012247438A5 - - Google Patents

Download PDF

Info

Publication number
JP2012247438A5
JP2012247438A5 JP2012198693A JP2012198693A JP2012247438A5 JP 2012247438 A5 JP2012247438 A5 JP 2012247438A5 JP 2012198693 A JP2012198693 A JP 2012198693A JP 2012198693 A JP2012198693 A JP 2012198693A JP 2012247438 A5 JP2012247438 A5 JP 2012247438A5
Authority
JP
Japan
Prior art keywords
inhibitor
cancer
leukemia
igfbp2
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012198693A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012247438A (ja
JP5816147B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012247438A publication Critical patent/JP2012247438A/ja
Publication of JP2012247438A5 publication Critical patent/JP2012247438A5/ja
Application granted granted Critical
Publication of JP5816147B2 publication Critical patent/JP5816147B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012198693A 2006-06-30 2012-09-10 Igfbp2インヒビター Active JP5816147B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81800406P 2006-06-30 2006-06-30
US60/818,004 2006-06-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009518353A Division JP5399900B2 (ja) 2006-06-30 2007-06-29 Igfbp2インヒビター

Publications (3)

Publication Number Publication Date
JP2012247438A JP2012247438A (ja) 2012-12-13
JP2012247438A5 true JP2012247438A5 (enExample) 2013-03-28
JP5816147B2 JP5816147B2 (ja) 2015-11-18

Family

ID=38783580

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009518353A Active JP5399900B2 (ja) 2006-06-30 2007-06-29 Igfbp2インヒビター
JP2012198693A Active JP5816147B2 (ja) 2006-06-30 2012-09-10 Igfbp2インヒビター
JP2013024276A Pending JP2013127473A (ja) 2006-06-30 2013-02-12 Igfbp2インヒビター

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009518353A Active JP5399900B2 (ja) 2006-06-30 2007-06-29 Igfbp2インヒビター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013024276A Pending JP2013127473A (ja) 2006-06-30 2013-02-12 Igfbp2インヒビター

Country Status (7)

Country Link
US (2) US20080112888A1 (enExample)
EP (2) EP2032989B2 (enExample)
JP (3) JP5399900B2 (enExample)
AT (1) ATE537450T1 (enExample)
CA (1) CA2655997A1 (enExample)
ES (1) ES2427924T3 (enExample)
WO (1) WO2008005469A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
US7811562B2 (en) * 2004-12-03 2010-10-12 Schering Corporation Biomarkers for pre-selection of patients for anti-IGF1R therapy
DK1848414T3 (da) 2005-02-03 2011-07-25 Gen Hospital Corp Fremgangsmåde til behandling af gefitinib-resistent cancer
EP1879587A2 (en) * 2005-04-15 2008-01-23 Schering Corporation Methods and compositions for treating or preventing cancer
AU2006311877A1 (en) 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
JP5399900B2 (ja) 2006-06-30 2014-01-29 メルク・シャープ・アンド・ドーム・コーポレーション Igfbp2インヒビター
KR20090095571A (ko) * 2006-11-01 2009-09-09 조지 매이슨 인털렉춸 프로퍼티즈, 인코퍼레이티드 암을 검출하고 조절하기 위한 방법
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009079587A2 (en) * 2007-12-18 2009-06-25 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
CA2718918A1 (en) * 2008-03-25 2009-11-26 Schering Corporation Methods for treating or preventing colorectal cancer
JP5646457B2 (ja) * 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
NZ589434A (en) * 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP5723769B2 (ja) * 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
SI2310011T1 (sl) 2008-06-17 2013-10-30 Wyeth Llc Antineoplastične kombinacije, ki vsebujejo HKI-272 in vinorelbin
WO2009154645A1 (en) * 2008-06-20 2009-12-23 Smithkline Beecham Corporation Methods for the treatment of central nervous system tumors
MX2010014574A (es) * 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
BRPI0916694B1 (pt) 2008-08-04 2021-06-08 Wyeth Llc uso de neratinibe em combinação com capecitabina para tratar câncer de mama metastático de erbb-2 positivo, kit e produto compreendendo os mesmos
MY150984A (en) 2008-12-12 2014-03-31 Boehringer Ingelheim Int Anti-agf antibodies
CA2756870A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted indolo-pyridinone compounds
CA2755789C (en) 2009-04-06 2016-01-19 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
MX2011011670A (es) * 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
BR112012008833A2 (pt) * 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8906374B2 (en) 2010-04-20 2014-12-09 Cedars-Sinai Medical Center Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors
US8741288B2 (en) * 2010-07-07 2014-06-03 Chang Gung Medical Foundation, Linkou Branch Protein markers for detecting liver cancer and method for identifying the markers thereof
DK2829881T3 (en) 2010-07-14 2017-12-04 Vision Tech Bio Pty Ltd Colorectal cancer diagnostic
SG188190A1 (en) 2010-08-03 2013-04-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2012019031A2 (en) * 2010-08-04 2012-02-09 Ohio University Biomarkers for growth hormone disorders
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US20130338033A1 (en) * 2011-01-27 2013-12-19 Virginia Commonwealth University Diagnostic and Prognostic Markers for Metastasis
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
CN102703502A (zh) * 2012-02-27 2012-10-03 同昕生物技术(北京)有限公司 Rta蛋白的制备方法及其在鼻咽癌检测试剂中的应用
CN110133298A (zh) * 2012-03-18 2019-08-16 株式会社资生堂 疾病样品分析装置、分析系统及分析方法
JP6298054B2 (ja) * 2012-08-09 2018-03-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心不全の診断
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
HK1216502A1 (zh) * 2012-11-02 2016-11-18 Repros Therapeutics Inc. 用於癌症治療的反式-克羅米芬
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
JP6480427B2 (ja) 2013-06-06 2019-03-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心不全後の再入院のバイオマーカー
CN105979961B (zh) 2014-02-05 2020-12-18 西达-赛奈医疗中心 用于治疗癌症和感染性疾病的方法和组合物
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
PE20231202A1 (es) 2020-10-14 2023-08-17 Viridian Therapeutics Inc Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法
WO2025054482A1 (en) * 2023-09-06 2025-03-13 Viridian Therapeutics, Inc. Pharmaceutical compositions of anti-igf-1r antibodies

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1319120C (en) 1985-04-01 1993-06-15 John Henry Kenten Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5656655A (en) 1994-03-17 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US6294349B1 (en) * 1999-03-01 2001-09-25 University Of Mississippi Medical Ctr. Method of diagnosing and monitoring malignant breast carcinomas
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
KR100666514B1 (ko) 1999-05-21 2007-02-28 브리스톨-마이어즈 스퀴브 컴페니 키나제의 피롤로트리아진 저해제
WO2000078341A1 (en) * 1999-06-21 2000-12-28 Murdoch Childrens Research Institute A method for the prophylaxis and/or treatment of medical disorders
GEP20053530B (en) 1999-10-19 2005-05-25 Merck & Co Inc Tyrosine Kinase Inhibitors, Pharmaceutical Compositions Containing Them and Use Thereof
US7001735B2 (en) * 2000-03-01 2006-02-21 Albert Einstein College Of Medicine Of Yeshiva University Glucose transporter/sensor protein and uses thereof
AU2002222939A1 (en) * 2000-07-19 2002-01-30 Takara Bio Inc. Method of detecting cancer
AU2002226877B2 (en) 2000-10-17 2006-01-12 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
UY27087A1 (es) 2001-01-05 2002-06-20 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
EP1401476A4 (en) * 2001-03-14 2006-03-08 Genentech Inc IGF ANTAGONIST PEPTIDES
MXPA04006980A (es) 2002-01-18 2004-11-10 Pf Medicament Anticuerpos novedosos anti-receptor del factor de crecimiento i tipo insulina, y usos de los mismos.
FR2834990A1 (fr) 2002-01-18 2003-07-25 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
FR2834900B1 (fr) 2002-01-18 2005-07-01 Pf Medicament Nouvelles compositions a activite anti-igf-ir et anti-egfr et leurs applications
FR2834991B1 (fr) 2002-01-18 2004-12-31 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
AU2003226051A1 (en) 2002-04-16 2003-11-03 Banyu Pharmaceutical Co., Ltd. Solid forms of salts with tyrosine kinase activity
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
TW200401638A (en) 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
TWI272271B (en) 2002-07-19 2007-02-01 Bristol Myers Squibb Co Process for preparing certain pyrrolotriazine compounds
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2003265349A1 (en) 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
PL378812A1 (pl) 2003-02-13 2006-05-29 Pfizer Products Inc. Zastosowania przeciwciał przeciw receptorowi insulinopodobnego czynnika wzrostowego I
JP2007528201A (ja) 2003-03-14 2007-10-11 ファルマシア・コーポレーション 癌治療のためのigf−i受容体に対する抗体
JP4473257B2 (ja) 2003-04-02 2010-06-02 エフ.ホフマン−ラ ロシュ アーゲー インスリン様成長因子i受容体に対する抗体及びその使用
EP2365001A3 (en) 2003-05-01 2012-03-28 Imclone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
EP1631689A2 (en) * 2003-05-28 2006-03-08 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
JP2007510434A (ja) * 2003-11-12 2007-04-26 シェーリング コーポレイション 多重遺伝子発現のためのプラスミドシステム
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
US7811562B2 (en) * 2004-12-03 2010-10-12 Schering Corporation Biomarkers for pre-selection of patients for anti-IGF1R therapy
EP1879587A2 (en) * 2005-04-15 2008-01-23 Schering Corporation Methods and compositions for treating or preventing cancer
KR20080019249A (ko) * 2005-06-15 2008-03-03 쉐링 코포레이션 안정한 항체 제형
JP5399900B2 (ja) 2006-06-30 2014-01-29 メルク・シャープ・アンド・ドーム・コーポレーション Igfbp2インヒビター
WO2008144345A2 (en) * 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators

Similar Documents

Publication Publication Date Title
JP2012247438A5 (enExample)
WO2008076278A4 (en) Methods of cancer treatment with igf1r inhibitors
JP2011519868A5 (enExample)
RU2010120674A (ru) Полностью человеческие анти-vegf-антитела и способы их применения
JP2011515478A5 (enExample)
JP2019503674A5 (enExample)
RU2018123481A (ru) Анти-lag3 антитела и антигенсвязывающие фрагменты
JP5816147B2 (ja) Igfbp2インヒビター
JP2016519091A5 (enExample)
MX2010012064A (es) Uso secuencial de agentes quimioterapeuticos citotoxicos para el tratamiento de cancer.
WO2010124009A2 (en) Fully human anti-vegf antibodies and methods of using
JP2017538673A5 (enExample)
RU2017145267A (ru) Модуляторы протеолиза на основе имидов и связанные с ними способы применения
CA2718918A1 (en) Methods for treating or preventing colorectal cancer
JP2013078341A (ja) 抗igf1r療法に対する感受性のバイオマーカー
JP2014516964A5 (enExample)
JP2014516964A (ja) 治療用抗igf1r合剤
US10512651B2 (en) Inhibition of MK2 in the treatment of cancer
CN111886010A (zh) 用于治疗与etbr激活相关的癌症的氘化化合物、组合物和方法
JPWO2021055705A5 (enExample)
US20160184356A1 (en) Arsenic-based treatment of cancers and inflammatory disorders
US20240122906A1 (en) Methods of treating melanoma with ripretinib
US20240209454A1 (en) Use of mutational signatures for multiple cancer types
US8470297B1 (en) FDG-pet evaluation of Ewing's sarcoma sensitivity
CN117693341A (zh) 用于治疗黑素瘤的瑞普替尼